Introduction {#s1}
============

γ-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous system (CNS) as opposed to glutamic acid, which is the primary excitatory CNS-neurotransmitter ([Figure 1](#pone-0052323-g001){ref-type="fig"}). Structurally, the two compounds are similar, and in fact GABA is formed *in vivo* by decarboxylation of glutamate. GABA~A~ receptors (GABA~A~Rs) are involved in a number of important functions such as cognition, learning, and memory and in disorders such as epilepsy, anxiety, schizophrenia, sleep disorders, and depression [@pone.0052323-Johnston1]. The GABA~A~Rs belong to the Cys-Loop receptor family that also includes nicotinic acetylcholine receptors (nAChRs), serotonine type 3 receptors (5-HT~3~Rs) and glycine receptors (GlyRs). All Cys-Loop receptors are homomeric or heteromeric assemblies of five subunits forming a central ion-conducting pore ([Figure 2](#pone-0052323-g002){ref-type="fig"}). The GABA~A~Rs and GlyRs conduct anions whereas nAChRs and 5-HT~3~Rs are cation selective. Each subunit is made up of an extracellular domain (ECD) consisting of mainly β-sheets, and a trans-membrane domain (TMD) consisting of four membrane spanning α-helices. GABA~A~R subunits include α~1--6~, β~1--3~, γ~1--3~, δ, ε, π, θ, ρ~1--3~ and the most abundant GABA~A~R subunit combination in the human CNS is the α~1~β~2~γ~2~ subtype where the endogenous neurotransmitter GABA binds in each of the interfaces between β~2~ and α~1~ subunits ([Figure 2](#pone-0052323-g002){ref-type="fig"}). A modulatory site for benzodiazepine (BZD) like compounds is found in a homologous position between α~1~ and γ~2~ subunits.

![Some classical GABA~A~ receptor ligands.\
GABA is the endogenous GAB~A~R agonist, muscimol a classical high-affinity agonist and THIP a muscimol analogue. Although not a GAB~A~R ligand, glutamate is included to illustrate the resemblance to GABA. Diazepam (DZP) belongs to the benzodiazepine class of compounds, which are allosteric GABA~A~ modulators. The DZP-NCS analogue attaches covalently to GABA~A~Rs and is included for validation purposes.](pone.0052323.g001){#pone-0052323-g001}

![Illustration of the GABA~A~R structural composition.\
**A**) Top view showing the pentameric assembly of α~1~, β~2~ and γ~2~ subunits and the location of binding sites for GABA and BZDs; **B**) Side view illustrating the extracellular domain (ECD) where agonists and benzodiazepines bind and the transmembrane domain (TMD); **C**) Zooming in on a GABA binding site at the subunit interface between β~2~ and α~1~ subunits, loop regions A--F mentioned in the text are shown (A: yellow, B: orange, C: red, D: purple, E: blue and F: pink).](pone.0052323.g002){#pone-0052323-g002}

Despite decades of research and a wealth of experimental and theoretical studies, the exact binding mode of key agonists including GABA is still unknown. The same is the case for the BZDs. Key agonists for the GABA binding site include the high affinity agonist muscimol [@pone.0052323-Johnston2], [@pone.0052323-Ebert1] and the partial agonist THIP [@pone.0052323-KrogsgaardLarsen1], [@pone.0052323-Frolund1], which is a structurally restrained muscimol analog ([Figure 1](#pone-0052323-g001){ref-type="fig"}). THIP was long in clinical trials for treatment of insomnia, but was discontinued. Still, the GABA~A~R agonist binding site is regarded a promising drug target and represents an intriguing alternative to the BZD binding site, which has long been the target for allosteric modulators including BZDs such as diazepam ([Figure 1](#pone-0052323-g001){ref-type="fig"}). BZDs are still one of the most prescribed classes of drugs for the treatment of insomnia, anxiety, and convulsions [@pone.0052323-McKernan1], [@pone.0052323-Rosahl1].

So far, drug discovery efforts have relied mainly on indirect structural insight from focused [@pone.0052323-Grant1]--[@pone.0052323-Frolund2] or unified pharmacophore models recapitulating the structure-activity relationships (SAR) of compounds synthesized during more than fifty years of active medicinal chemistry research in the field [@pone.0052323-KrogsgaardLarsen2], [@pone.0052323-Clayton1]. Homology models, on the other hand, have had little practical impact on the design process despite a number of models reported in the literature [@pone.0052323-Berezhnoy1]--[@pone.0052323-OMara1]. The models were mainly built using the homologous acetylcholine binding proteins (AChBPs) as templates. The AChBPs have supplied insight into a number of structural features of Cys-Loop receptors. The position of loops A--F ([Figure 2](#pone-0052323-g002){ref-type="fig"}) known from mutational studies to participate in ligand binding were established with the first AChBP structure [@pone.0052323-Brejc1]. A high degree of flexibility has later on been observed for the C-loop, which is a hair-pin shaped loop that embraces the orthosteric binding sites and shields from the solvent [@pone.0052323-Hansen1]. It was observed that depending on the type of ligand in the binding site, the C-loop either exists in a closed (agonist) conformation or an open (antagonist) conformation allowing large inhibitors to enter the binding site. This C-loop movement has also been speculated to be linked to the activation mechanism of Cys-Loop receptors [@pone.0052323-Chang1].

Although, the AChBPs have proven valuable templates for modeling of nAChRs [@pone.0052323-Brejc1], [@pone.0052323-Dutertre1]--[@pone.0052323-Harpsoe1] they suffer from a lack of conservation of binding site residues with respect to GABA~A~Rs, which makes them unsuitable as stand-alone templates for GABA~A~R homology modeling. To compensate for the lack of conservation of binding site residues, we have recently reported a novel strategy for GABA~A~R modeling utilizing experimental restraints and multiple templates including AChBPs from different species [@pone.0052323-Hansen1], [@pone.0052323-Celie1], a mouse α~1~ nAChR subunit [@pone.0052323-Dellisanti1], and the bacterial orthologs from Gloeobacter violaceus (GLIC) [@pone.0052323-Bocquet1] and Erwinia chrysanthemii (ELIC) [@pone.0052323-Hilf1] in the alignment generation and model building steps [@pone.0052323-Sander1]. In particular, inclusion of the ELIC structure adds important conserved binding site residues to the pool of template structures. Using this strategy, a reliable model of the GABA~A~R ECD with focus on the orthosteric ligand binding interface of the α~1~β~2~γ~2~ GABA~A~R in its non-activated (antagonized) state was obtained. The model was consistent with experimental data and capable of rationalizing the structure activity relationships (SAR) of a series of GABA~A~R orthosteric antagonists [@pone.0052323-Sander1].

With the recent release of atomic resolution structures of a eukaryotic glutamate gated chloride channel (GluCl) [@pone.0052323-Hibbs1] from the nematode *C. elegans*, the molecular basis for modeling of pentameric ligand gated anion channels has improved considerably. The GluCl structure has an unprecedented high sequence identity compared to the GABA~A~R; 30%, 36%, and 31% relating to α1, β2 and γ2 subunits, respectively, and even higher identities with respect to the ligand binding cores (∼48% in an 8 Å radius from glutamate in GluCl). The GluCl structure was crystallized in presence of its agonist glutamate and was captured in its presumed open state.

In this report we demonstrate the use of the GluCl structure as template for construction of a GABA~A~ receptor homology model comprising both the ECD and TMD portions of the receptor. We show that when *combined* with the structure of the bacterial ELIC channel, a reliable GABA~A~R model based entirely on full length receptor X-ray structures can be obtained. The model is built in the open state with GABA in the two orthosteric binding sites between β~2~ and α~1~ subunits. The BZD binding site between the α~1~ and γ~2~ subunit is adapted to the positive allosteric modulator diazepam (DZP). The model is capable of explaining SARs, mutational data, and data from studies of covalent linking of a DZP-derivative to cysteine mutants of the receptor. Therefore, the validated model might also serve as a tool for structure guided design of new agonists and allosteric modulators and may form the link to interpretation of previously reported pharmacophore models [@pone.0052323-Ghoshal1], [@pone.0052323-Clayton1], [@pone.0052323-Frolund3] in a structural context.

Methods {#s2}
=======

Homology modeling {#s2a}
-----------------

### Templates, sequences and sequence alignment {#s2a1}

The X-ray structure of GluCl co-crystallised with glutamate (PDB code 3RIF) [@pone.0052323-Hibbs1] was used as primary template for homology modeling of the most abundant subtype of the GABA~A~R, α~1~β~2~γ~2~. In a few important regions with low sequence identity to GluCl the bacterial homologue ELIC (PDB code 2VL0) [@pone.0052323-Hilf2], which has a 20% sequence identity to GluCl, was included as template as well. The extent to which each template structure was used is specified in [Figure 3](#pone-0052323-g003){ref-type="fig"}, in which the definitions for the general secondary structural elements of Cys-Loop receptors referred to throughout this paper are also indicated. The rationale for including ELIC as template in the areas highlighted in [Figure 3](#pone-0052323-g003){ref-type="fig"} were the following: 1) In the β1 and β2 sheets the ELIC structure contains aromatic residues in positions 19 and 38 resembling those in the GABA~A~R; 2) In the β6--β7-loop (Cys-Loop) and in the β7 and β10 strands ELIC was included as template for the β~2~ subunit to capture information about the conformations of and interactions between GABA~A~R β~2~E155 and β~2~R207; 3) In the M2--M3-loop ELIC was included as template due to the presence of Pro residues in homologous positions.

![Alignment of protein sequences from GluCl, GLIC, ELIC and the human α~1~, β~2~, and γ~2~ GABA~A~R subunits.\
The GluCl sequence was used as template for homology modeling throughout the GABA~A~R subunits, and ELIC was included as a template in the regions marked with blue boxes. The secondary structure deduced from the X-ray structure of GluCl is shown above the alignment (red shapes denote α-helices, and green arrows denote β-strands), whereas historically assigned loop regions are indicated below the alignment. As in the GluCl structure the M3--M4 intracellular loop of GABA~A~R sequences was replaced by an AGT tri-peptide linker. Residues comprising the binding sites (within 8 Å of Glu in the GluCl structure and pointing towards the binding site) are colored pink (Glu and GABA binding site) and cyan (BZD binding site). Binding site residues conserved with respect to the templates are indicated as follows: **+** conserved in both GABA and BZD binding sites; **\*** conserved in the GABA binding sites; **.** conserved in the BZD binding site. For details on calculation of binding site sequence identities see [Figure S1](#pone.0052323.s002){ref-type="supplementary-material"}.](pone.0052323.g003){#pone-0052323-g003}

The sequence alignment was obtained following the procedure reported by *Sander et al.* [@pone.0052323-Sander1] First, a structural alignment of the two template structures was generated using Pymol 1.3 [@pone.0052323-Berman1]. Subsequently, all human GlyR α-subunits and all human GABA~A~R subunits were aligned to the GluCl sequence as profile alignments with iteration on the last alignment using ClustalX v. 2.0.12 [@pone.0052323-Larkin1]. The GlyR α-subunits represent the closest human homologs to GluCl and were included to aid identification of semi-conserved motifs. In three regions, namely, 1) in and after the N-terminal α-helix, 2) in loop F, and 3) in loop C, manual adjustments of the generated alignment were performed to ensure proper alignment of conserved motifs. 1) In the N-terminal α-helix the motif represented by the GABA~A~ α~1~ sequence [IL]{.ul}DR[LL]{.ul}DG[Y]{.ul}DNR[LRP]{.ul} was misaligned by ClustalX due to the presence of insertions in the GlyR α-subunit sequences and the GABA~A~R ρ-subunit sequences. Therefore, this motif was reestablished as described by Sander *et al*. [@pone.0052323-Sander1] 2) In loop F varying sequence lengths and low sequence identity resulted in a poor alignment and many gaps. We identified a hydrophobic-X-hydrophobic motif (corresponding to [V]{.ul}V[V]{.ul} in the GABA~A~R α~1~-subunit), forming a short β-strand of three residues in GluCl, ELIC, the bacterial ion channel GLIC (PDB ID: 3EAM) the mouse nAChR α~1~-subunit (PDB ID: 2QC1) and in AChBPs from Aplysia californica (PDB ID: 2BYQ) and Bulinus truncatus (PDB ID: 2BJ0) [@pone.0052323-Hansen1], [@pone.0052323-Dellisanti1], [@pone.0052323-Bocquet1], [@pone.0052323-Celie2]. The generated alignment was manually adjusted to re-establish this motif in the GABA~A~R sequences. 3) In loop C, the automatically generated alignment from ClustalX had gaps in the GABA~A~R sequences in the β-sheet regions. These were manually moved to the tip of the loop as it is generally accepted that the length of loop C varies between families and subtypes of Cys-Loop receptors. 4) Finally, we truncated the M3--M4 intracellular loop and inserted an AGT tripeptide according to the GluCl structure. The manually adjusted alignment is reported in [Figure 3](#pone-0052323-g003){ref-type="fig"}.

Prior to model building the GluCl X-ray structure was prepared as follows. The FAB fragments (chains F--O) as well as all heteroatoms were removed except glutamates in the orthosteric binding sites between chains A, B and C, D. Then the α-carboxylic acid moiety was deleted from the glutamate ligands, resulting in a GluCl template structure with GABA in the two orthosteric binding sites between chains A, B and C, D.

### Model building, evaluation and selection {#s2a2}

The program MODELLER 9v7 [@pone.0052323-Sali1] was used for homology modeling using the "automodel class", which includes no other restraints than spatial restraints gathered from the sequence alignment. 100 models were generated, and the refinement level "refine.slow" was applied. GABA molecules were modeled into the two β~2~-α~1~ subunit interfaces in the GABA~A~ receptor model as rigid bodies.

The final model selection was performed according to the consensus scoring approach described by Sander *et al.* [@pone.0052323-Sander1] using the ProSA z-score [@pone.0052323-Sippl1], the energy according to the OPLS 2001 force field [@pone.0052323-Kaminski1], [@pone.0052323-Jorgensen1] as implemented in Maestro [@pone.0052323-Schrdinger1], and the MODELLER built in scoring functions, *molpdf* and DOPE score [@pone.0052323-Sali1]. The consensus 10 best scoring models were assessed visually for physico-chemical requirements such as packing of hydrophobic residues in hydrophobic environments and solvent exposure of charged residues. Also, the interactions between the modeled GABA molecule and the receptor model were assessed as part of the selection criteria.

Model refinement {#s2b}
----------------

The selected model was subjected to the protein preparation wizard in Maestro [@pone.0052323-Schrdinger1], which adds hydrogen atoms, assigns bond orders, creates disulphide bonds and samples hydrogen bond networks. Furthermore, the protein preparation wizard assesses the protonation state of His, Lys, Arg, Glu, and Asp. As is seen in the GluCl structure E293 interacts with R245 and D316, indicating that this residue exists in its protonated form. Therefore, the corresponding five Glu residues (two α~1~E302, two β~2~E298, and one γ~2~E313) in the homology model, which also coordinates to Arg and Asp were protonated. The protein preparation wizard and the PROPKA web server [@pone.0052323-Olsson1]--[@pone.0052323-Li1] further supported this assessment. All other residues were kept at their standard protonation states (neutral His, protonated Lys and Arg and deprotonated Glu and Asp). Finally, an energy minimization with a flat-bottomed Cartesian constraint and a convergence threshold set to an RMSD of 0.3 Å was performed.

The model was further refined as follows: 1) The rotameric state of α~1~R66 (in chain D) was optimized for optimal bidentate interactions with GABA using the side chain refinement tool in Prime [@pone.0052323-Schrdinger2]; 2) Hydrogen bond networks between the GABA molecules and the receptor model were manually optimized by selecting appropriate rotamers of α~1~T129 similar to the homologous S121 in the GluCl structure; 3) Loop A (residues 99--102) in the BZD site carrying α~1~H101 was sampled using the loop sampling protocol in Prime [@pone.0052323-Schrdinger2] in order to obtain an orientation of α~1~Asn102 in agreement with the template structure; 4) A rotamer of β~2~K196 able to make a salt bridge with β~2~E153 was selected ([Table 1](#pone-0052323-t001){ref-type="table"}).

10.1371/journal.pone.0052323.t001

###### Overview of mutations affecting the function of the GABA~A~R or the binding of orthosteric ligands.

![](pone.0052323.t001){#pone-0052323-t001-1}

  Residue                                                                                                   Proposed function/feature                                                                                                                Reference(s)
  ------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------
  Structural features                                                                                                                                                                                                 
  β~2~E153, β~2~K196                                                                       Intra-subunit salt bridges important for receptor function.                                                                                      [@pone.0052323-Venkatachalan1]
  Ligand-binding features                                                                                                                                                                                             
  α~1~F64                                                              Affects binding of bicuculline and gabazine and SCAM identified residue to be part of binding site.                                             [@pone.0052323-Boileau1]--[@pone.0052323-Holden1], [@pone.0052323-Sigel3]
  α~1~R66                                                                                        Identified by SCAM to be part of binding site.                                                                                    [@pone.0052323-Boileau1], [@pone.0052323-Holden1]
  α~1~L117                                                                    Identified by SCAM to be part of binding site. Also binding of gabazine is affected.                                                                              [@pone.0052323-Kloda1]
  α~1~R119                                     Predicted by SCAM to line binding site. Mutation to Lys results in 180 fold reduced EC~50~ for GABA and inability of muscimol and gabazine to bind.                               [@pone.0052323-Kloda1], [@pone.0052323-WesthHansen1]
  α~1~T129                                                                                           Predicted by SCAM to line binding site.                                                                                        [@pone.0052323-Jansen1], [@pone.0052323-Kloda1]
  α~1~R131                                                                                           Predicted by SCAM to line binding site.                                                                                                    [@pone.0052323-Kloda1]
  β~2~Y97                                              Identified by SCAM to be part of binding site. Artificial amino acid mutagenesis indicates participation in pi-cation interaction.                                         [@pone.0052323-Padgett1], [@pone.0052323-Boileau2]
  β~2~E155                                                       Cys mutation gives rise to spontaneously open channel. Predicted to be connected to gating and ligand binding.                                                                 [@pone.0052323-Newell1]
  β~2~Y157                       Mutagenesis to Cys, Asn, Phe, and Ser indicate that this residue must be aromatic. Artificial amino acid mutagenesis does not indicate pi-cation interaction with this residue.       [@pone.0052323-Newell1], [@pone.0052323-Amin1], [@pone.0052323-Padgett1]
  β~2~F200                                                                    Cys mutation significantly affects gabazine affinity as well as receptor activation.                                                                              [@pone.0052323-Wagner2]
  β~2~S201                                                                           Cys mutation affects gabazine affinity as well as receptor activation.                                                                                     [@pone.0052323-Wagner2]
  β~2~T202                                                    Ala and Cys mutations renders receptor essentially inactive. Ser mutation is accepted but decreases EC~50~ slightly.                                                  [@pone.0052323-Amin1], [@pone.0052323-Wagner2]
  β~2~G203                                                                      Cys mutation severely affects affinity of gabazine and activation of the recptor.                                                                               [@pone.0052323-Wagner2]
  β~2~Y205                   Crucial residue that must be aromatic. Mutations to Ser and Asn renders the receptor inactive, and mutation to Cys affects both gabazine binding and receptor activation very severely.                [@pone.0052323-Amin1], [@pone.0052323-Wagner2]
  β~2~R207                                                                      Affects GABA binding and un-binding rates. Predicted to be part of binding site.                                                                   [@pone.0052323-Wagner1], [@pone.0052323-Wagner2]

All data in the table are in agreement with our GABA~A~R model.

Ligand docking and binding site characterization {#s2c}
------------------------------------------------

GABA, muscimol, and THIP were created in their ionized states in Maestro 9.2 [@pone.0052323-Maestro1] followed by conformational searches with MacroModel 9.9 (default settings) [@pone.0052323-MacroModel1]. The global energy minimum conformations were identified and used as input conformations for docking. The agonists were docked into the orthosteric binding site between chains A and B using the Glide Induced Fit Docking (IFD) protocol [@pone.0052323-Sherman1], [@pone.0052323-Sherman2] and the Extra Precision (XP) scoring function [@pone.0052323-Friesner1]. By default the IFD procedure allows amino acid side chains to adapt to the docked ligand in a 5 Å sphere. Docking poses were selected based on compliance with mutational data ([Table 1](#pone-0052323-t001){ref-type="table"}) and common interaction patterns in the binding site. Finally, selected ligand poses including residues in an 8 Å sphere were energy minimized to convergence using MacroModel 9.9.

The program GRID [@pone.0052323-Goodford1], [@pone.0052323-MolecularDiscovery1] was used to characterize the non-bonded water interaction properties of the vacant binding pocket between chains A and B (GABA site) of the refined model using the water probe (OH2). A grid spacing of 0.33 Å was used and all other settings were kept at their default values.

Quantum mechanical (QM) calculations was performed using Jaguar 7.8 [@pone.0052323-Jaguar1]. For muscimol, a relaxed coordinate scan was performed to determine conformational energies when varying the amino-methyl side chain dihedral angle in a step size of 10° between 0--180°. The Poisson-Bolzmann aqueous solvation model [@pone.0052323-Tannor1] and otherwise default settings were selected (B3LYP/6-31G\*\*). Gas-phase energies were extracted from the results in order to consider only the steric energies.

The docking procedure described for the agonists was also attempted for DZP at the BZD site, but none of the obtained poses could be rationalized by experimental data. DZP was docked using its assumed bioactive conformation as input for docking [@pone.0052323-Young1]--[@pone.0052323-Simonyi2]. QM partial charges were calculated using Jaguar 7.6 default settings. Subsequently, DZP was manually docked to the BZD binding site according to experimental evidence: Docked DZP should 1) have the Cl-substituent positioned in the vicinity of or pointing towards α~1~H101, α~1~N102 [@pone.0052323-Tan1], α~1~G157, α~1~V202, and α~1~V211 [@pone.0052323-Tan2], 2) have the C-3 atom positioned in the vicinity of or directed towards α~1~S205 and α~1~T206 [@pone.0052323-Tan3], 3) have the *N*-methyl substituent directed towards an exit from the binding cavity [@pone.0052323-Sigel1], and 4) have the pending phenyl ring positioned in a lipophilic cavity [@pone.0052323-Zhang1], [@pone.0052323-Sternbach1]. Following manual positioning of DZP, the α~1~-γ~2~ interface was allowed to adapt to DZP using the side chain prediction tool in Prime in which backbone and residue sampling within 4 Å of DZP was performed. As a final step, Prime performs a minimization of the complex, the docked ligand and the surrounding residues in question (backbone and side chains). The protein and the ligand were thus allowed to adapt to each other. The final model was further validated using 1) mutational studies from the literature ([Table 2](#pone-0052323-t002){ref-type="table"}), 2) *in silico* covalent docking of a Cys-reactive DZP derivative, and 3) assessment of SAR data from the literature in a structural context.

10.1371/journal.pone.0052323.t002

###### Overview of mutations affecting the function of the GABA~A~R or the ability of BZD binding site ligands to bind to the BZD binding site.

![](pone.0052323.t002){#pone-0052323-t002-2}

  Residue                                                                                        Proposed function/feature                                                                                                                        Reference(s)
  ----------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------
  Ligand-binding features                                                                                                                                                                    
  α~1~F99                                                May be involved in π-π stacking or might in some other way interact directly with ligands of the BZD type.                                                              [@pone.0052323-Tan1], [@pone.0052323-Hanson1]
  α~1~H101                                               May be involved in π-π stacking or might in some other way interact directly with ligands of the BZD type.                                              [@pone.0052323-Berezhnoy2], [@pone.0052323-Davies1], [@pone.0052323-Wingrove2]
  α~1~Y159                                                 Mutation to Ala, Cys or Ser severely affects binding affinity of BZDs. Residue lines the binding site.                                                      [@pone.0052323-Tan1], [@pone.0052323-Tan2], [@pone.0052323-Amin2]
  α~1~G200                                                                          This residue lines a distal part of the binding site                                                              [@pone.0052323-Hanson1], [@pone.0052323-Buhr3], [@pone.0052323-Schaerer1], [@pone.0052323-Wingrove2]
  α~1~V202                                                                          This residue lines a distal part of the binding site                                                                                         [@pone.0052323-Hanson1], [@pone.0052323-Buhr3]
  α~1~T206                                                          Mutation to Ala, Val, and Cys severely affects binding affinity of BZD-site ligands.                                      [@pone.0052323-Tan2], [@pone.0052323-Tan3], [@pone.0052323-Buhr1], [@pone.0052323-Sigel2], [@pone.0052323-Schaerer1]
  α~1~G207                                                                  Mutation to Cys severely affects binding affinity of flunitrazepam.                                                                                               [@pone.0052323-Tan2]
  α~1~Y209                                       Aromatic functionality of the residue at this position is required for high-affinity binding of BZD binding site ligands.                                           [@pone.0052323-Hanson1], [@pone.0052323-Amin2], [@pone.0052323-Buhr1]
  γ~2~F77                                        Aromatic functionality of the residue at this position is required for high-affinity binding of BZD binding site ligands.                                                       [@pone.0052323-Buhr2]--[@pone.0052323-Sigel2]
  γ~2~M130                                                                                  This residue lines the binding site                                                                                                 [@pone.0052323-Hanson1], [@pone.0052323-Sigel2]
  Covalently modified mutants                                                                                                                                                                
  α~1~G157                       7-NCS-derivatives of imidazo-BZDs react covalently with Cys-mutants of this residue suggesting the 7-position of imidazo-BZDs points towards this residue.                                                   [@pone.0052323-Tan2]
  α~1~Y159                           The NCS-derivative of imidazo-BZD does not react covalently with Cys-mutants of this residue. 7-substituent is not directed towards this residue.                                                        [@pone.0052323-Tan2]
  α~1~V202                           7-NCS-derivatives of imidazo-BZDs react covalently with Cys-mutants of this suggesting the 7-position of imidazo-BZDs points towards this residue.                                                       [@pone.0052323-Tan2]
  α~1~S205                                  The 3-NCS-derivative of flunitrazepam reacts covalently with the Cys-mutant, forming a constitutively positively modulated receptor.                                                              [@pone.0052323-Tan3]
  α~1~S206                                  The 3-NCS-derivative of flunitrazepam reacts covalently with the Cys-mutant, forming a constitutively positively modulated receptor.                                                              [@pone.0052323-Tan3]
  α~1~V211                       7-NCS-derivatives of imidazo-BZDs react covalently with Cys-mutants of this residue suggesting the 7-position of imidazo-BZDs points towards this residue.                                                   [@pone.0052323-Tan2]

All data in the table is in agreement with our GABA~A~R model.

As a validation of the DZP binding mode, the Cys-reactive BZD derivative DZP-NCS [@pone.0052323-Tan1], [@pone.0052323-Tan2], [@pone.0052323-Berezhnoy2], [@pone.0052323-Berezhnoy3] ([Figure 1](#pone-0052323-g001){ref-type="fig"}) was covalently docked to an α~1~H101C variant of the homology model using the "covalent docking" module in Prime. The covalent docking module works by eliminating two atoms in order to form a new bond between the reacting molecules/species. Since Prime cannot handle simultaneous reduction of a double bond and formation of a new bond, the isothiocyanato group of DZP-NCS was reduced to a methanethioamide group prior to submission of the job. The thiol-hydrogen was defined as the leaving receptor atom. The conformation of the attachment residue was sampled and all other residues were kept fixed.

Finally, a 48 ns molecular dynamics simulation was performed to assess the stability of the final GABA~A~R model. Details are supplied as Model S1.

Results and Discussion {#s3}
======================

With the improved structural templates available from efforts in structural biology it is now possible to build α~1~β~2~γ~2~ GABA~A~R models based entirely on full length receptor templates. We have created a full-length α~1~β~2~γ~2~ GABA model mainly based on the glutamate bound GluCl X-ray structure and partly using the bacterial Cys-Loop homolog ELIC as an additional template. The model has been optimized in the GABA and BZD binding sites for the agonists GABA, muscimol and THIP and the modulator diazepam. The GluCl X-ray structure with glutamate bound was crystallized in an open state with a negatively charged ion in the lower part of the TMD [@pone.0052323-Hibbs1]. The ELIC structure, on the other hand, was crystallized in a putatively closed state in absence of a bound ligand [@pone.0052323-Hilf1]. Since only a few residue positions in our model have been modeled based on the ELIC structure, the overall architecture of the α~1~β~2~γ~2~ GABA model is obtained from the GluCl structure. Therefore, we regard our model as being in the open state.

Model assessment {#s3a}
----------------

The pentameric GABA~A~R α~1~β~2~γ~2~ ECD-TMD homology model comprised 1676 residues distributed with 335, 334, and 333 residues in α~1~, β~2~, and γ~2~ GABA~A~R subunits respectively. The selected model had good backbone geometry with 98.8% of the residues in favorable or additionally allowed regions in the Procheck v. 3.5.4 Ramachandran plot [@pone.0052323-Laskowski1]. All residues in disallowed regions in the Ramachandran plot were situated in solvent exposed loop regions distant to the binding site. The ProSA z-scores for the selected homology model were within the accepted area for X-ray structures from the PDB. Furthermore, stability of the model was assessed by a 48 ns molecular dynamics calculation which showed essentially no drift after termination of the equilibration protocol (see [Figure S2](#pone.0052323.s003){ref-type="supplementary-material"}).

### Validation by mutational data {#s3a1}

Both the GABA and BZD binding sites have been heavily investigated by site-directed mutagenesis ([Tables 1](#pone-0052323-t001){ref-type="table"} and [2](#pone-0052323-t002){ref-type="table"}). Among these mutations, some have been used to suggest which residues line the binding sites, which residues interact directly with different ligands, and which are regarded as important structural features of the receptor. These experimental data, including those listed in [Tables 1](#pone-0052323-t001){ref-type="table"} and [2](#pone-0052323-t002){ref-type="table"} that were not directly imposed during model refinement, are explainable by our homology model with the suggested poses of GABA and DZP as described below.

Agonist binding model {#s3b}
---------------------

### GABA {#s3b1}

The X-ray structure of GluCl with glutamate bound presents a good indication of how GABA would bind to the GABA receptors. Our α~1~β~2~γ~2~ GABA model confirms that a similar GABA binding mode interacts well with the receptor and is in agreement with the experimental mutational data presented in [Table 1](#pone-0052323-t001){ref-type="table"}. In this binding mode GABA forms salt bridges with α~1~R66 and β~2~E155 and hydrogen bonds with α~1~T129, β~2~T202, and the backbone of β~2~S156. Finally, there is a π-cation interaction with β~2~Y205. The GABA binding mode from our docking study is illustrated in [Figure 5A](#pone-0052323-g005){ref-type="fig"}. As described in the methods section GABA was modeled into the binding pockets of our receptor model as rigid bodies, which allowed space for GABA in the binding site. However, hydrogen bonding network was not optimized in the modeling process, hence, a few side chains needed adjustments as described in the methods section.

![Agonist binding modes determined by induced fit docking.\
A) GABA (green), B) THIP (pink) and C) muscimol (cyan) are shown in the orthosteric binding site at the interface between the β~2~ subunit (teal) and the α~1~ subunit (smudge).](pone.0052323.g005){#pone-0052323-g005}

The GABA~A~ orthosteric binding site apparently resembles the GluCl glutamate binding site to a large extent. However, there are a few crucial differences. Newell *et al.* [@pone.0052323-Newell1] identified β~2~E155 to be vital for GABA~A~ ligand binding and channel gating. This residue is lacking in the GluCl receptor, but is present in ELIC ([Figure 4A](#pone-0052323-g004){ref-type="fig"}), a receptor, which is known to be activated by e.g. GABA [@pone.0052323-Thompson1], an important reason for including the ELIC structure as modeling template. The position of β~2~E155 in our receptor model is in perfect hydrogen bonding distance to the protonated amine of GABA, thereby forming a salt bridge deeply buried in the pocket and surrounded by a number of aromatic residues (so-called aromatic box). β~2~E155 is flanked by β~2~R207 intruding from outside the pocket. This residue has also been investigated experimentally and shown to affect GABA binding and un-binding [@pone.0052323-Wagner1], which makes sense if GABA binds as predicted here, since there is a clear electrostatic interaction between β~2~R207 and GABA through β~2~E155. Two other important residues that are non-conserved between GluCl and GABA~A~, but present in ELIC, are the β~2~F200 (C-loop) and α~1~F64 (D-loop). They serve as components of the aromatic box, taking part in shielding the positive charge in an enclosure of aromatic planes.

![Conserved template residues.\
The figure shows residues that are conserved or homologous to GABA~A~R binding site residues from the GluCl X-ray structure (PBD ID 3RIF) as grey sticks and the bacterial Cys-Loop receptor homolog, ELIC (PDB ID 2VL0) as purple sticks. Glutamate as co-crystallized with GluCl is shown in yellow, where the structure corresponding to GABA is shown as sticks and the α-carboxylic acid removed prior to homology modeling is shown as lines. A) GABA binding site and B) BZD binding site.](pone.0052323.g004){#pone-0052323-g004}

When GABA was re-docked into the binding site, a similar binding pose was identified ([Figure 5A](#pone-0052323-g005){ref-type="fig"}). This extended conformation of GABA has previously been determined by X-ray crystallography [@pone.0052323-Steward1], [@pone.0052323-Tomita1] and by conformational search found as one of several low energy conformations. However, the GABA alkyl chain is quite flexible, and it is likely that it is not entirely fixed in the protein bound state. The distance between the two charges is approximately 5 Å in the identified pose. However, even if the GABA alkyl chain should be slightly bent, resulting in a shorter inter-charge distance, optimal interactions can be obtained in the binding pocket by GABA interacting with the backbone carbonyl of β~2~Y157 in place of β~2~S156. Indeed, previous pharmacophore models disagree on which should be the exact charge-charge distance in GABA~A~ agonists. However, it has generally been proposed to be in the range 4--5 Å [@pone.0052323-Ghoshal1] and in fact, our GABA~A~R model predicts that agonist with different inter-charge distances (4--5 Å) may bind equally well to the receptor. Apart from the salt bridge to β~2~E155, the positive charge of GABA is further surrounded by the aromatic ring of β~2~Y205 and makes a hydrogen bond to the backbone β~2~S156 (B-loop) similar to glutamate in the GluCl template structure. Mutational data show that β~2~Y205 is crucial for binding gabazine, a selective, competitive GABA~A~ antagonist, and for channel gating and that this residue must be aromatic for the receptor to be functional ([Table 1](#pone-0052323-t001){ref-type="table"}) [@pone.0052323-Amin1]--[@pone.0052323-Gynther1]. The carboxylic acid of GABA is fixed between β~2~ and α~1~ subunits by a bidentate interaction with α~1~R66 and hydrogen bonds with the two threonines β~2~T202 (C-loop) and α~1~T129. Again, these interactions make perfect sense in the light of published experimental data ([Table 1](#pone-0052323-t001){ref-type="table"}). Mutations of α~1~T202 have a crucial impact on GABA activation of the GABA~A~ receptor. Mutation to Ala or Cys renders the receptor virtually inactive, while some function is retained with a α~1~T202S mutation [@pone.0052323-Amin1], [@pone.0052323-Wagner2]. α~1~R66C mutations have shown a 300--500 fold decrease in EC~50~ and the residue was shown by the substituted cysteine accessibility method (SCAM) to be part of the binding pocket [@pone.0052323-Boileau1], [@pone.0052323-Jansen1]. This residue has long been suspected to interact with the carboxylic acid of GABA [@pone.0052323-Boileau1], [@pone.0052323-Holden1]--[@pone.0052323-Cromer2]. However, α~1~R119 (in GABAρ1), α~1~R131 and β~2~R207 have also been hypothesized to perform this interaction [@pone.0052323-Wagner1], [@pone.0052323-Harrison1], [@pone.0052323-Kloda1]. Based on the GluCl X-ray structure and available mutational data, the evidence for α~1~R66 to be the arginine interacting with the GABA carboxylic acid is quite strong. β~2~R207 interacts with GABA through β~2~E155 as discussed above. In our model α~1~R119 (conserved in GluCl) has an important structural role, as it links the α-subunit to the C-loop of the β-subunit (hydrogen bond to the backbone of β~2~T202) thereby forming a "roof" on top of the agonist binding site as well as an enforced closed state of the C-loop. A closed C-loop has long been regarded necessary for obtaining the active state of Cys-Loop receptors [@pone.0052323-Hansen1], [@pone.0052323-Celie2], [@pone.0052323-Hibbs2]. α~1~R131 is found lining the back wall of the binding site behind α~1~F64, where it interacts with α~1~D62 and the backbone of β~2~D101. Nevertheless, the flexible α~1~R131 could also reach β~2~Y97 to form a π-cation interaction. This residue was identified by *Padgett et al.* [@pone.0052323-Padgett1] to participate in a π-cation interaction in the GABA~A~ receptors and they suggested that the cation should originate from the GABA molecule. However, based on our model a π-cation interaction between GABA and β~2~Y97 is unlikely. Indeed, it has generally caused difficulty to generate a GABA~A~ receptor model with the aromatic ring of β~2~Y97 facing the binding pocket, which has not changed with the improved template GluCl [@pone.0052323-Sander1], [@pone.0052323-Padgett1]. The authors suggested α~1~R131 as an alternative cation source in the binding site, and this would fit our model. The mutational consequences of β~2~Y97C and α~1~R131C could instead originate from perturbation of the activation mechanism.

### THIP and muscimol {#s3b2}

The docked poses of the other hallmark agonists THIP and muscimol are illustrated in [Figure 5B--C](#pone-0052323-g005){ref-type="fig"}. Poses with similar interactions as described above for GABA were identified, however, with some differences as discussed below.

The rigid THIP is able to make the same interactions as GABA. The 3-hydroxy-isoxazole moiety, a bio-isostere of the carboxylic acid in GABA, interacts with α~1~R66, β~2~T202 and α~1~T129 similar to GABA. Furthermore, the protonated amine forms a salt bridge to β~2~E155 and a pi-cation interaction with the important β~2~Y205.

The pose obtained for muscimol at first seemed erroneous, due to a slight displacement of the charged amine compared to GABA and THIP ([Figure 5C](#pone-0052323-g005){ref-type="fig"}). In this pose the positive charge is tucked in between the two C-loop aromatic residues β~2~Y205 and β~2~F200, however, the salt bridge to β~2~E155 is retained. The acidic moiety of the 3-hydroxy-isoxazole was perfectly placed similar to THIP and GABA. Therefore, the only difference compared to the GABA receptor interactions is a π-cation interaction with β~2~F200 instead of a backbone interaction to the B-loop. Despite numerous docking attempts and efforts to manually reposition muscimol to a pose similar to GABA and THIP, when energy minimized, the muscimol amino-methyl side chain kept "flipping" back. A dihedral drive using QM calculations revealed that the reason was a preferred torsional angle (O-C-C-N) of the muscimol amino-methyl side chain at ca. 45° ([Figure 6](#pone-0052323-g006){ref-type="fig"}). If both charges of muscimol were to overlay with the charges of GABA in the bound state, it would result in a torsional angle of ≥90° which would result in a conformational energy penalty of ≥3 kcal/mol ([Figure 6](#pone-0052323-g006){ref-type="fig"}). Such a high conformational energy is unlikely for a high affinity ligand as muscimol (K~i~ = 6 nM), which binds to GABA~A~ receptors with an even higher affinity than GABA itself (K~i~ = 18 nM) [@pone.0052323-Bostrm1], [@pone.0052323-Madsen1]. The identified binding mode of muscimol depicted in [Figure 5C](#pone-0052323-g005){ref-type="fig"} has an O-C-C-N torsional angle of ca. 60°, which corresponds to a conformational energy penalty of ∼0.6 kcal/mol. Still, we were puzzled if no interaction with a B-loop backbone carbonyl should take place when muscimol binds. This is a generally accepted binding feature of Cys-Loop receptor agonists [@pone.0052323-Brejc1], [@pone.0052323-Hansen1], [@pone.0052323-Rohde1]. A GRID interaction energy calculation using the water probe (OH2) prior to optimization of the orthosteric receptor pocket revealed a region of high specificity for a water molecule (\<−11 kcal/mol) next to the B-loop backbone carbonyls from β~2~S156 and β~2~Y157 ([Figure 7A](#pone-0052323-g007){ref-type="fig"}). When placing muscimol and a water molecule in the orthosteric binding site, it was found that hydrogen bonding distances were optimal and allowed muscimol a more extensive bonding pattern within the binding site than GABA. When also including the GABA binding pose, it was apparent that the GABA positive charge and the water molecule occupy the same region in the pocket ([Figure 7B](#pone-0052323-g007){ref-type="fig"}). We therefore propose that muscimol binds in concert with a water molecule as illustrated in [Figure 7A](#pone-0052323-g007){ref-type="fig"} resulting in a low conformational energy penalty and optimal interactions with the GABA~A~ orthosteric binding pocket.

![Conformational energy profile for dihedral drive of the amino-methyl side chain of muscimol.\
B3LYP/6-31G\*\* energies.](pone.0052323.g006){#pone-0052323-g006}

![Region suited for a tightly bound water molecule identified in agonist site.\
A GRID calculation at the agonist binding site, using the water probe, identified two regions of strong binding interaction energy (−11 kcal/mol). One region is overlapping with the acidic moiety of agonists and the other region is situated next to the backbone of β~2~S156 and β~2~Y157 (grey mesh). The calculation was performed in absence of agonist in the binding site. In the picture, the site has been optimized for muscimol as described in the methods section. A) When a water molecule is placed between muscimol and the B-loop backbone, perfect hydrogen bonding distances are obtained, resulting in optimal interactions between the high affinity ligand muscimol and the GABA receptor. B) When also GABA is included in the site, it is obvious that the water molecule would make up for the backbone interaction that GABA is predicted to make.](pone.0052323.g007){#pone-0052323-g007}

BZD binding model {#s3c}
-----------------

As described in the methods section DZP was manually positioned in a binding mode ([Figure 8](#pone-0052323-g008){ref-type="fig"}) satisfying the listed criteria deduced from experimental literature data followed by optimization of side chains in the binding pocket. The resulting model agrees to a large extent with the binding mode of DZP, recently described by Richter *et al.* [@pone.0052323-Richter1] despite being built on different templates and is further in agreement with available mutational data ([Table 2](#pone-0052323-t002){ref-type="table"}) indicating that residues α~1~F99, [@pone.0052323-Tan1], [@pone.0052323-Hanson1] α~1~H101, [@pone.0052323-Berezhnoy2], [@pone.0052323-Davies1] α~1~Y159, [@pone.0052323-Hanson1], [@pone.0052323-Amin2] α~1~Y209, [@pone.0052323-Hanson1], [@pone.0052323-Amin2], [@pone.0052323-Buhr1] γ~2~F77, [@pone.0052323-Buhr2]--[@pone.0052323-Sigel2] and γ~2~M130 [@pone.0052323-Hanson1], [@pone.0052323-Sigel2] line the binding pocket. As was the case for the GABA othosteric binding site, the GluCl template contributes to the homology model with a higher similarity than the previously available templates. Furthermore, the ELIC X-ray structure adds information about a few BZD binding site residues (γ~2~Y58 and γ~2~F77) lacking in the GluCl structure ([Figure 4B](#pone-0052323-g004){ref-type="fig"}). In brief, the obtained binding mode of DZP orients the chlorine atom of DZP towards α~1~H101 and positions it underneath the C-loop pointing towards the base of the C-loop ([Figure 8](#pone-0052323-g008){ref-type="fig"}). The pending phenyl ring is positioned in a narrow cavity between α~1~F99 (A-loop), α~1~Y159 (B-loop), and γ~2~F77 (D-loop) in the bottom of the binding site shielded from solvent exposure. The carbonyl is positioned in a manner similar to the carboxylic acid of GABA in the orthosteric binding site. It links the two subunits at the interface by hydrogen bonds to α~1~T206 (C-loop) and γ~2~T142 (D-loop). Finally, the polarized N-methyl group is situated near the C-loop enabling polar contacts with α~1~T206, α~1~Y209 and the backbone of α~1~Y159 ([Figure 8](#pone-0052323-g008){ref-type="fig"}).

![DZP binding mode.\
A) The assumed biologically active binding mode of DZP (gray) at the interface between the α~1~ (smudge) and γ~2~ (firebrick) subunits. In this conformation the C-3 points upwards and the pending phenyl substituent is directed inwards. B) Covalently attached DZP-NCS (cyan) overlaid with DZP (gray). Only moderate differences between the docked and the covalently attached ligands exist.](pone.0052323.g008){#pone-0052323-g008}

BZD pharmacophore models based on SAR data have predicted a lipophilic pharmacophoric feature (in the traditional BZD pharmacophore terminology named L1) to be an essential part of BZDs [@pone.0052323-Zhang1], [@pone.0052323-DiazArauzo1]. In DZP this feature corresponds to the fused aromatic ring system, which in the model is buried beneath the C-loop and shielded from solvent by the hydrophobic residues α~1~V202, C~β~ of α~1~T206, α~1~Y209, and α~1~V211. α~1~V202 was predicted by mutational studies to line the binding site [@pone.0052323-Hanson1], [@pone.0052323-Buhr3] and α~1~T206 and α~1~Y209 are both essential for ligand binding to the BZD site [@pone.0052323-Tan2], [@pone.0052323-Tan3], [@pone.0052323-Hanson1], [@pone.0052323-Amin2], [@pone.0052323-Buhr1], [@pone.0052323-Sigel2], [@pone.0052323-Schaerer1]. SAR studies [@pone.0052323-Zhang1], [@pone.0052323-DiazArauzo1] state that the pharmacophoric feature, L1, should be accommodated in a narrow cavity that does not tolerate substitution at other positions than that corresponding to C-7 in DZP (see [Figure 1](#pone-0052323-g001){ref-type="fig"}). Our proposed DZP binding mode comply well with this notion, since substitution at positions C-8 and C-9 would lead to steric interference with backbone atoms of the C-loop. Substitution at the C-6 position would lead to steric clashes with α~1~H101 and γ~2~F99 explaining why this is not tolerated. [@pone.0052323-Zhang1], [@pone.0052323-Sternbach1] However, the cavity, in which the DZP C-7 substituent (pharmacophoric feature L2), the chlorine atom, is positioned, has to be spacious enough to accommodate larger substituents (e.g. a nitro group as seen in flunitrazepam) [@pone.0052323-Sternbach1]. This is indeed the case in our model. The position of the pharmacophoric feature, L2, is further supported by studies of covalent labeling of cysteine mutants [@pone.0052323-Tan1], [@pone.0052323-Tan3]. In these studies, a DZP derivative, where the chlorine atom is substituted to a cysteine-reactive isothiocyanate group (DZP-NCS, [Figure 1](#pone-0052323-g001){ref-type="fig"}), is covalently linked to cysteine mutants of the receptor. Covalent labeling of α~1~H101C leads to a constitutively positively allosterically modulated receptor, which indicates that the ligand is covalently attached in an orientation matching the orientation of DZP in its bioactive conformation. We replicated this study *in silico* through covalent docking of DZP-NCS and obtained a pose complying with experimental data ([Table 2](#pone-0052323-t002){ref-type="table"}) and resembling the otherwise established binding mode ([Figure 8B](#pone-0052323-g008){ref-type="fig"}) among the top scoring poses. As can be seen from the overlay of the docked DZP and the covalently attached DZP-NCS, the two ligands obtain similar binding modes, the primary difference being caused by a slight rotation of the scaffold of DZP-NCS to allow for covalent attachment of DZP-NCS. Furthermore, labeling of α~1~S205C, α~1~T206C mutants by a C-3 DZP-NCS probe strongly indicates the C-3 of DZP-NCS to point towards the tip of the C-loop [@pone.0052323-Tan3]. Labeling with an imidazobenzodiazepine-NCS derivative of the partial negative allosteric modulator Ro15-4513, further indicates that C-7 should be oriented towards α~1~H101, α~1~N102, [@pone.0052323-Tan1] α~1~G157, α~1~V202, and α~1~V211, [@pone.0052323-Tan2] also correlating with our model.

Available SAR data for BZDs indicate that the pending phenyl ring (pharmacophoric feature L3) is positioned in a narrow cavity [@pone.0052323-Zhang1], [@pone.0052323-Sternbach1]. Substitution at the ring is only tolerated in the 2′-position, whereas substitution in positions 3′ and 4′ are poorly tolerated. [@pone.0052323-Zhang1], [@pone.0052323-Sternbach1] Our model agrees with these observations, as the pending phenyl ring is positioned in an aromatic box formed by α~1~F99, α~1~H101, α~1~Y159, γ~2~F99, and γ~2~N128. In addition to satisfying ligand requirements of aromatic burial, the described position of the pending phenyl ring also serves as a strong contact point between the α~1~ and the γ~2~ subunits.

The remaining lipophilic pharmacophoric features L3 (corresponding to the phenyl group in DZP) and L~DI~ of the traditional benzodiazepine pharmacophore models [@pone.0052323-Clayton1], [@pone.0052323-Zhang1], [@pone.0052323-DiazArauzo1] are situated near residues α~1~V202 and α~1~V211, and γ~2~A79, γ~2~L140, γ~2~Y58, γ~2~Q56, respectively. The latter feature is not occupied by DZP but is important for binding and function of other BZD binding site ligands, e.g. indol-3-yl-glyoxylamides [@pone.0052323-Taliani1].

An additional point of inter subunit contact is the carbonyl group of DZP. This carbonyl is positioned under the tip of the C-loop and is in an optimal position to form hydrogen bonds across the interface through α~1~T206 and γ~2~T142, similar to how the GABA carboxylate binds to β~2~T202 and α~1~T129 in the orthosteric binding site. Indeed, mutation of α~1~T206 has been identified in several studies to severely affect binding affinity of BZDs ([Table 2](#pone-0052323-t002){ref-type="table"}).

Further interactions between DZP and the receptor model are formed by the polarized *N*-methyl group. Due to the position of the methyl group on a nitrogen atom, the hydrogen atoms are more polarized than they would be if the methyl group was attached to an aliphatic carbon, thereby being able to form polar contacts with the receptor. This has been seen previously in AChBP X-ray structures [@pone.0052323-Rohde1]. In our model these hydrogen atoms are positioned in the negatively charged electrostatic field of the backbone carbonyl oxygen of α~1~Y159 and the hydroxyl groups of α~1~T206 and α~1~Y209. This also explains the beneficial effect of including the *N*-methyl substituent in BZDs. [@pone.0052323-Sternbach1]

Interestingly, when comparing the validated binding modes of GABA and DZP in their respective binding sites it is intriguing to see that corresponding residues, in particular β~2~T202/α~1~T206, β~2~Y205/α~1~Y209, β~2~Y97/α~1~F99, β~2~Y157/α~1~Y159, α~1~T129/γ~2~T142 and α~1~F64/γ~2~F77 are responsible for contacts between receptor and ligands and that both GABA and DZP in a similar manner bridge neighboring subunits. We have recently shown that a third binding site exists in the α~4~α~4~ interface of the so-called low sensitivity nAChR (α~4~)~3~(β~2~)~2~ and hypothesized that this could be the nicotinic pendant of the BZD binding site [@pone.0052323-Harpsoe2]. The structural model presented here may help to design experiments to investigate this hypothesis and thus contribute to the ongoing debate of the mechanism of action of BZDs [@pone.0052323-Hanson1], [@pone.0052323-Amin2], [@pone.0052323-CampoSoria1]--[@pone.0052323-Morlock1].

Conclusions {#s4}
===========

The model and subsequent validation by available experimental data shows that reliable GABA~A~R models can be obtained using novel full length receptor templates. In addition to serving as a model of how agonists and modulators may bind to the GABA~A~R, the model may help to guide mutational studies unraveling the mechanism by which agonists, BZDs and other allosteric modulators work.

Compared to earlier templates used for homology modeling of the GABA~A~Rs the emergence of the X-ray structure of the GluCl ion channel has significantly increased the insight into the architecture of anionic Cys-Loop receptors. With the new templates, sequence identities with respect to GABA sequences are as high as 36% and even up to 48% if narrowing the focus to the agonist binding site. Hence, the information on side chain conformations in the binding site of GABA~A~R/anion channels of the Cys-Loop receptor family has now improved considerably. Previously published homology models have mainly been modeled with AChBP as template. With sequence identities as low as 19% combined with the lack of a TMD as is the case when using AChBPs as templates, homology models based on the GluCl structure represents a big step forward.

Based on homology modeling, advanced docking methods, QM calculations and a vast amount of collected experimental data, we have identified binding hypotheses for GABA, muscimol, THIP and diazepam and optimized the binding sites accordingly. Our GABA~A~R model is modeled in the open state according to the GluCl glutamate bound structure and is intended for creating binding hypotheses of agonists or BZD site modulators. The model is made available in Model S1.
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